Table 2.
Summary of the quantitative variation of all annotated metabolites that were found significant in any of the comparisons, grouped by the family of compounds. 36W-ATH: 36 weeks atherosclerosis without colchicine treatment; 18 W: 18 weeks atherosclerosis; 36W-CCH, 36 weeks with colchicine treatment.
| Biochemical class | Compound names | CODE | Technique | ID level50 | 36W-ATH vs. 18 W log2FC |
36W-CCH vs. 36W-ATH log2FC | FACTOR: ATHEROSCLEROSIS p-value | FACTOR: COLCHICINE p-value | FACTORS INTERACTION p-value |
|---|---|---|---|---|---|---|---|---|---|
| Glucose derivative | Glucosamine 1-phosphate | GNP | GC/MS | 2 | −3.15 | 0.86 | 3.3·10−02 | NS | 1.1·10−02 |
| Short-Chain Organic Acids | Pyruvic acid | PYR | GC/MS | 2 | −1.06 | −0.74 | 2.2·10−03 | 9.6·10-03 | NS |
| Acetoacetate | ACA | GC/MS | 2 | −0.42 | 0.71 | NS | NS | 3.1·10−02 | |
| Oxalic acid | OXA | GC/MS | 2 | −0.67 | −0.07 | 2.2·10−03 | 3.5·10−02 | NS | |
| Pentanoic acid | PEN | GC/MS | 2 | −0.79 | 0.02 | 3.4·10−02 | 1.3·10−02 | 2.9·10−02 | |
| Amino acids and amino acids derivatives | Phenylalanine | PHE | LC/MS(+) | 2 | −0.21 | −1.05 | 4.4·10−02 | 8.7·10−03 | NS |
| Pyroglutamine | PYG | CE/MS | 3 | 1.07 | −0.40 | 3.0·10−03 | NS | NS | |
| Acetyl-Lysine | ACL | CE/MS | 2 | 0.60 | −0.29 | 4.0·10−04 | NS | NS | |
| 2-Aminoadipic acid | AAA | CE/MS | 2 | 0.64 | −0.15 | 4.7·10−03 | NS | NS | |
| Glycyl-Glutamate | GLG | CE/MS | 2 | 0.44 | −0.12 | 8.9·10−03 | NS | NS | |
| 5-hydroxy-tryptophan | OHW | GC/MS | 2 | −1.46 | 0.48 | NS | NS | 2.0·10−02 | |
| Kynurenine | KYN | CE/MS | 2 | −0.23 | 1.16 | 9.0·10−04 | 4.9·10-04 | 2.1·10−04 | |
| Cystathionine | CYN | CE/MS | 2 | 0.59 | −0.21 | 2.4·10−03 | NS | NS | |
| Cystine | CYD | CE/MS | 2 | 0.72 | 0.11 | 2.5·10−03 | NS | NS | |
| Proline betaine | PRB | CE/MS | 3 | −0.28 | −0.67 | NS | 1.7·10−02 | NS | |
| Prolylhydroxyproline | POP | CE/MS | 3 | −0.62 | −0.25 | 1.6·10−02 | NS | NS | |
| Acyl Carnitine | ACR | LC/MS(+) | 3 | 1.37 | 0.26 | 9.2·10−05 | NS | NS | |
| Bile acids | Glycohydroxyoxocholanoate [glycol deoxy/chenodeoxy/ursodeoxy cholate] | GDC-1 | LC/MS(−) | 2 | 1.99 | 1.59 | 4.3·10−02 | 4.2·10−02 | NS |
| Glycohydroxyoxocholanoate [glycol deoxy/chenodeoxy/ursodeoxy cholate] | GDC-2 | LC/MS(+) | 2 | 1.53 | 1.18 | 9.7·10−03 | 2.6·10−02 | NS | |
| Glycohydroxyoxocholanoate glucuronide [glyco deoxy/chenodeoxy/ursodeoxy cholate glucuronide] | GDG-1 | LC/MS(+) | 3 | 0.88 | 0.18 | 7.8·10−03 | NS | NS | |
| Glycohydroxyoxocholanoate glucuronide [glyco deoxy/chenodeoxy/ursodeoxy cholate glucurornide] | GDG-2 | LC/MS(−) | 2 | 1.25 | 0.65 | 1.3·10−05 | NS | NS | |
| Glycohydroxyoxocholanoate sulfate [glyco deoxy/chenodeoxy/ursodeoxy cholate sulfate] | GDS | LC/MS(−) | 3 | 1.56 | 0.51 | 1.4·10−04 | NS | NS | |
| Glycolithocholate | GLC-1 | LC/MS(−) | 3 | 1.87 | 0.17 | 4.4·10−03 | NS | NS | |
| Glycolithocholate | GLC-2 | LC/MS(+) | 3 | 1.87 | 1.20 | 1.8·10−02 | NS | NS | |
| Glycolithocholate glucuronide | GLG-1 | LC/MS(−) | 3 | 0.99 | −0.11 | 2.3·10−03 | NS | NS | |
| Glycolithocholate glucuronide | GLG-2 | LC/MS(−) | 2 | 0.94 | 0.27 | 6.1·10−04 | NS | NS | |
| Glycolithocholate sulfate | GCS-1 | LC/MS(−) | 3 | 1.67 | 1.64 | 3.8·10−02 | 4.7·10-02 | NS | |
| Glycolithocholate sulfate | GCS-2 | LC/MS(+) | 2 | 1.41 | 1.28 | 4.6·10−02 | 3.6·10−02 | NS | |
| Glycotrihydroxyoxocholanoate [glycocholate] | GCA-1 | LC/MS(+) | 2 | 1.58 | 0.47 | 4.2·10−05 | NS | NS | |
| Glycotrihydroxyoxocholanoate [glycocholate] | GCA-2 | LC/MS(+) | 2 | 0.68 | 0.56 | 8.0·10−06 | NS | NS | |
| Hydroxyoxocholanoate [deoxy/chenodeoxy/ursodeoxy cholate] | DCA-2 | LC/MS(+) | 3 | 0.11 | 0.99 | 3.9·10−02 | 3.5·10−03 | NS | |
| Hydroxyoxocholanoate [deoxy/chenodeoxy/ursodeoxy cholate] | DCA-1 | LC/MS(−) | 3 | 0.14 | 1.01 | NS | 4.9·10−02 | NS | |
| Hydroxyoxocholanoate glucuronide [deoxy/chenodeoxy/ursodeoxy cholate glucuronide] | DCG | LC/MS(+) | 3 | 0.68 | 0.04 | 1.5·10−03 | NS | NS | |
| Hydroxyoxocholanoate sulfate [deoxy/chenodeoxy/ursodeoxy cholate sulfate] | DCS | LC/MS(−) | 3 | 1.91 | 0.12 | 6.9·10−03 | NS | NS | |
| Lithocholate glucuronide | LCG-1 | LC/MS(−) | 2 | 0.99 | 0.61 | 4.6·10−05 | 4.9·10−02 | NS | |
| Lithocholate glucuronide | LCG-2 | LC/MS(−) | 3 | 0.78 | 0.56 | 1.4·10−03 | NS | NS | |
| Trihydroxycholestenoic acid/Dihydroxyoxocholestanoic acid [cholate] | BIA | LC/MS(+) | 3 | 0.67 | 0.23 | 1.5·10−04 | NS | NS | |
| Sterols (non bile acids) | Cholestene | CHN | GC/MS | 2 | 0.60 | −0.24 | 3.9·10−05 | NS | NS |
| Cholesterol | CHO | LC/MS(+) | 3 | −0.89 | 0.07 | NS | 1.6·10−02 | NS | |
| Hydroxypentaoxolanostenoic acid | HOC | LC/MS(−) | 2 | 0.38 | 0.67 | 1.0·10−02 | 4.2·10−02 | NS | |
| Pregnanediol glucuronide | PRG | LC/MS(−) | 3 | 1.26 | 0.40 | 6.6·10−05 | NS | NS | |
| Sterol Sulfate | STS | LC/MS(+) | 3 | 1.34 | 0.10 | 4.7·10−04 | NS | NS | |
| Sterol-456 | STE-456-1 | LC/MS(−) | 3 | 1.38 | 0.22 | 2.1·10−04 | NS | NS | |
| Sterol-456 | STE-456-2 | LC/MS(+) | 3 | 1.36 | 0.22 | 3.0·10−04 | NS | NS | |
| Sterol-460 | STE-460 | LC/MS(+) | 3 | 0.30 | 0.74 | NS | 4.8·10−02 | NS | |
| Sterol-608 | STE-608 | LC/MS(−) | 3 | 1.74 | 0.15 | 2.1·10−04 | NS | NS | |
| Sterol-622 | STE-622 | LC/MS(+) | 4 | 1.09 | 0.39 | 5.3·10−03 | NS | NS | |
| Other lipids | LysoPC(16:0(OH)) | LPC(OH)−1 | LC/MS(+) | 3 | 0.96 | 0.19 | 7.5·10−03 | NS | NS |
| LysoPC(16:0(OH)) | LPC(OH)−2 | LC/MS(+) | 3 | 1.03 | 0.12 | 7.5·10−03 | NS | NS | |
| LysoPC(20:5) | LPC(20:5) | LC/MS(−) | 3 | 1.42 | −0.15 | 4.1·10−04 | NS | NS | |
| Lysophosphatidylcholine | LPC-1 | LC/MS(−) | 2 | 1.13 | 0.11 | 1.9·10−04 | NS | NS | |
| Lysophosphatidylcholine | LPC-2 | LC/MS(−) | 3 | 0.76 | −0.38 | 3.1·10−02 | NS | 2.8·10−03 | |
| Biliverdin | BVD-1 | LC/MS(+) | 3 | 0.47 | 0.61 | 3.9·10−03 | NS | NS | |
| Biliverdin | BVD-2 | LC/MS(+) | 3 | 0.24 | 0.93 | 3.0·10−03 | NS | 1.9·10−02 |